CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands |
Sep. 30, 2018 |
Mar. 31, 2018 |
| Current assets: |
|
|
| Cash and cash equivalents |
$ 23,282
|
$ 17,583
|
| Short-term investments |
124,612
|
43,968
|
| Research and development incentives receivable |
2,221
|
2,389
|
| Prepaid expenses and other current assets |
1,752
|
763
|
| Total current assets |
151,867
|
64,703
|
| Property, plant and equipment, net |
420
|
370
|
| Research and development incentives receivable - long term |
343
|
|
| Restricted cash |
1,186
|
78
|
| Total assets |
153,816
|
65,151
|
| Current liabilities: |
|
|
| Accounts payable |
2,072
|
1,993
|
| Accrued expenses and other current liabilities |
1,672
|
3,171
|
| Total current liabilities |
3,744
|
5,164
|
| Deferred rent, net of current portion |
36
|
52
|
| Warrant liability |
0
|
1,642
|
| Total liabilities |
3,780
|
6,858
|
| Commitments and contingencies (Note 13) |
|
|
| Convertible preferred stock (Series Seed, A and B), $0.001 par value; 0 and 1,975,968 shares authorized as of September 30, 2018 and March 31, 2018 respectively;0 and 1,925,968 shares issued and outstanding as of September 30, 2018 and March 31, 2018, respectively |
|
86,361
|
| Stockholders' Equity (Deficit): |
|
|
| Common stock, $0.001 par value; 150,000,000 and 27,314,288 shares authorized (inclusive of 0 and 26,258 shares of common A stock) as of September 30, 2018 and March 31, 2018, respectively; 31,553,672 and 5,007,485 shares issued and outstanding (inclusive of 0 and 26,258 shares of common A stock) as of September 30, 2018 and March 31, 2018, respectively |
32
|
5
|
| Additional paid-in capital |
196,664
|
1,097
|
| Accumulated deficit |
(45,437)
|
(28,932)
|
| Accumulated other comprehensive loss |
(1,223)
|
(238)
|
| Total stockholders' equity (deficit) |
150,036
|
(28,068)
|
| Total liabilities, convertible preferred stock and stockholders' equity (deficit) |
$ 153,816
|
$ 65,151
|